Compare SYPR & KRRO Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.
Current Price
Current Price
| Metric | SYPR | KRRO |
|---|---|---|
| Founded | 1997 | 2014 |
| Country | United States | United States |
| Employees | 713 | N/A |
| Industry | Industrial Machinery/Components | Biotechnology: Pharmaceutical Preparations |
| Sector | Industrials | Health Care |
| Exchange | Nasdaq | Nasdaq |
| Market Cap | 68.9M | 58.6M |
| IPO Year | 1994 | 2019 |
| Metric | SYPR | KRRO |
|---|---|---|
| Price | $3.39 | $10.80 |
| Analyst Decision | | Buy |
| Analyst Count | 0 | 10 |
| Target Price | N/A | ★ $74.17 |
| AVG Volume (30 Days) | ★ 457.0K | 186.9K |
| Earning Date | 11-12-2025 | 03-17-2026 |
| Dividend Yield | N/A | N/A |
| EPS Growth | N/A | N/A |
| EPS | ★ N/A | N/A |
| Revenue | ★ $123,055,000.00 | $7,371,000.00 |
| Revenue This Year | N/A | $145.49 |
| Revenue Next Year | N/A | N/A |
| P/E Ratio | N/A | N/A |
| Revenue Growth | N/A | ★ N/A |
| 52 Week Low | $1.42 | $5.20 |
| 52 Week High | $4.74 | $55.89 |
| Indicator | SYPR | KRRO |
|---|---|---|
| Relative Strength Index (RSI) | 58.65 | 61.48 |
| Support Level | $2.27 | $9.88 |
| Resistance Level | $3.78 | $10.93 |
| Average True Range (ATR) | 0.56 | 0.80 |
| MACD | 0.02 | 0.46 |
| Stochastic Oscillator | 42.25 | 79.08 |
Sypris Solutions Inc is a USA-based company engaged in providing truck components, oil and gas pipeline components, and aerospace and defense electronics. The company offers a range of manufacturing, engineering, design, and other technical services. The business activity of the firm is functioned through Sypris Technologies and Sypris Electronics segments. Sypris Technologies segment is engaged in the sales of machined, welded, and heat-treated steel components for heavy commercial vehicle and high-pressure energy pipeline applications whereas the Sypris Electronics segment is engaged in the sale of manufacturing services, technical services, and products to customers in the market for aerospace and defense electronics. Sypris derives the revenue from the Technologies segment.
Korro Bio Inc is a biopharmaceutical company with a mission to discover, develop, and commercialize a new class of genetic medicines based on editing RNA, enabling the treatment of both rare and highly prevalent diseases. It is generating a portfolio of differentiated programs that are designed to harness the body's natural RNA editing process to effect a precise yet transient single base edit. By editing RNA instead of DNA, Korro Bio is expanding the reach of genetic medicines by delivering additional precision and tunability.